Agilent's defensive laboratory ecosystem, 65% recurring revenue, Ignite-led margin recovery, and reshoring catalysts support constructive five-year upside despite elevated valuation and Waters-BD competition.
Agilent Technologies Inc is a premier global provider of analytical and clinical laboratory technologies, delivering critical instruments, consumables, software, services, and scientific expertise to help customers address complex regulatory and research questions [cite: 1, 2]. With an active install base across more than 285,000 laboratories worldwide and a workforce of approximately 18,100 employees, the company operates at the center of global scientific research and diagnostic testing [cite: 3, 4]. The enterprise generates its revenue through three highly specialized, market-focused operating segments: the Life Sciences and Diagnostics Markets Group, the Applied Markets Group, and the Agilent CrossLab Group [cite: 5].
The company's core products include high-performance liquid and gas chromatography systems, mass spectrometers, molecular and atomic spectroscopy devices, genomics microarrays, immunohistochemistry systems, and companion diagnostics assays [cite: 5, 6, 7, 8]. These physical platforms are integrated with proprietary laboratory software, automation solutions, and specialized services to manage end-to-end scientific workflows [cite: 5]. Geographically, the company features a well-balanced revenue footprint, with the Americas representing the largest region, followed closely by the Asia-Pacific and European markets [cite: 9].
The primary customers of the organization include laboratory managers, principal investigators, clinical pathologists, quality control technicians, and manufacturing engineers [cite: 2, 5]. These clients operate across six major end markets: pharmaceuticals and biotechnology, diagnostics and clinical workflows, chemical and advanced materials, environmental and forensics, food safety, and academic or governmental research [cite: 5, 10].
Customers choose this company over alternatives due to its superior measurement precision, robust instrument reliability, and the comprehensive workflow integration enabled by its proprietary informatics software [cite: 5, 11]. Crucially, once a specific analytical method is validated and registered under strict regulatory protocols, the time, expense, and compliance risks of switching to a competitor's hardware or software are exceptionally high [cite: 11]. This operational lock-in yields a highly defensive business model that supports a durable stream of high-margin, recurring aftermarket consumables and service contracts [cite: 10].
| Operational Parameter | Consolidated Global Value (FY2025) |
|---|---|
| Total Net Revenue | \$6.95 Billion [cite: 1, 3] |
| Active Laboratory Workstations | 285,000 workstations [cite: 3] |
| Global Workforce | 18,100 employees [cite: 4] |
| Americas Revenue (Share %) | \$2.81 Billion ($40.39\%$) [cite: 9] |
| Asia Pacific Revenue (Share %) | \$2.22 Billion ($31.94\%$) [cite: 9] |
| Europe Revenue (Share %) | \$1.92 Billion ($27.68\%$) [cite: 9] |
To align directly with customer end markets and enhance cross-selling efficiency, the enterprise restructured its operations in late 2024 into three streamlined business segments [cite: 4, 5]. Understanding what is actually sold within these segments is essential to evaluating the underlying economic engine:
Consolidated Sales
|
---------------------------------|---------------------------------
| | |
LDG (38%) ACG (42%) AMG (20%)
- High-Throughput LC/MS - Service Contracts - Gas Chromatography
- Tissue Pathology Assays - Chromatography Consumables - Vacuum Technology
- CDMO Oligo Services - OpenLab Enterprise Software - Spectroscopy
The enterprise-wide operating system, designated as the Ignite program, acts as the primary internal margin expansion driver [cite: 15, 16]. Originally launched to drive execution excellence and decision-making speed, the Ignite program has systematically consolidated procurement, simplified internal reporting structures, and doubled pricing realization across major product lines [cite: 15]. In its first twelve months, the program yielded over \$150 million in annualized savings, directly supporting operating margin normalization after recent tariff shocks [cite: 17, 18].
Externally, the business is benefiting from structural reshoring trends [cite: 17]. Federal trade policies and the implementation of Section 232 import tariffs on foreign patented active ingredients have prompted large biopharmaceutical and semiconductor manufacturers to prioritize domestic capital projects [cite: 17]. Management estimates this domestic manufacturing shift will increase the addressable market by approximately \$1.0 billion by 2030, with early revenue contributions materializing in late fiscal year 2026 and continuing into fiscal year 2027 [cite: 17].
The company's competitive moat is characterized by high customer switching costs [cite: 11]. Analytical procedures in clinical diagnostic assays and biopharmaceutical quality control are tightly integrated into regulatory filing processes [cite: 2, 11]. Re-validating a method with a competitor's system requires significant labor, capital, and regulatory re-filing fees [cite: 11].
The competitive landscape is structured as a tight oligopoly where the top five players control roughly $75\%$ of the market [cite: 11]. The company holds a prominent position within this group, commanding an estimated $20\%$ share of its target markets [cite: 11].
Key competitors include Thermo Fisher Scientific, Danaher Corporation, Waters Corporation, Mettler-Toledo, and Bruker Corporation [cite: 10, 19, 20]. Competition in the clinical space has intensified following the early 2026 merger of Waters Corporation and the BD Biosciences & Diagnostics division [cite: 21]. This \$17.5 billion transaction created a pro forma diagnostic giant with expected calendar 2025 revenues of \$6.5 billion, putting competitive pressure on Agilent's diagnostic market share [cite: 21].
Agilent has countered this competitive challenge by leveraging its direct-sales distribution model and pursuing targeted acquisitions, such as Biocare Medical and the late-2024 takeover of Canadian CDMO BIOVECTRA for \$925 million [cite: 2, 4, 7]. These strategic transactions expand the company's capabilities in high-growth tissue diagnostics and biotherapeutic manufacturing workflows [cite: 7, 22].
| Competitor Name | Estimated Annual LTM Revenue | Core Market Position vs. Agilent |
|---|---|---|
| Thermo Fisher Scientific | \$45.19 Billion [cite: 23] | Market leader in total scale; primary competitor across LC, MS, and clinical consumables [cite: 10, 20]. |
| Danaher Corporation | \$24.77 Billion [cite: 23] | Market leader in clinical tissue diagnostics via Leica Biosystems; competes directly with Agilent's Dako and Biocare portfolios [cite: 10, 12, 24]. |
| Waters Corporation | \$6.45 Billion (Pro Forma) [cite: 21, 25] | Strengthened positioning in liquid chromatography and clinical diagnostics via the BD Biosciences merger [cite: 21, 26]. |
| Bruker Corporation | \$3.45 Billion [cite: 23] | Highly focused on specialized mass spectrometry and research-grade systems [cite: 20]. |
The enterprise reported its preliminary third-quarter fiscal year 2026 financial results on August 26, 2026, for the period ending July 31, 2026 [cite: 27, 28]. The results demonstrated strong execution, with reported net revenue reaching \$1.878 billion, representing a year-over-year increase of $8.1\%$ reported and $7.3\%$ on a core/non-GAAP basis compared with the third quarter of fiscal 2025 [cite: 27, 28].
This revenue performance exceeded the consensus analyst estimate of \$1.84 billion by $2.08\%$ [cite: 29, 30]. Operating cash flow generation was a notable highlight, climbing to \$519 million for the quarter, up $43.4\%$ year-over-year [cite: 14].
| Financial Metric | Q3 FY2026 Preliminary Result | Q3 FY2025 Comparative | YoY % Change |
|---|---|---|---|
| Net Revenue | \$1.878 Billion [cite: 27, 28] | \$1.738 Billion [cite: 27, 28] | $+8.1\%$ [cite: 27] |
| GAAP Net Income | \$362 Million [cite: 27, 28] | \$336 Million [cite: 27, 28] | $+7.7\%$ [cite: 27, 28] |
| GAAP Diluted EPS | \$1.28 [cite: 27, 28] | \$1.18 [cite: 27, 28] | $+8.5\%$ [cite: 27, 28] |
| Non-GAAP Net Income | \$459 Million [cite: 28, 31] | \$390 Million [cite: 28, 31] | $+17.7\%$ [cite: 28, 31] |
| Non-GAAP Diluted EPS | \$1.62 [cite: 28, 31] | \$1.37 [cite: 28, 31] | $+18.2\%$ [cite: 28, 31] |
| GAAP Operating Margin | $23.6\%$ [cite: 28, 32] | $20.7\%$ [cite: 27, 28] | $+290\text{ bps}$ [cite: 28] |
| Non-GAAP Operating Margin | $28.3\%$ [cite: 28, 31] | $25.1\%$ [cite: 28, 31] | $+320\text{ bps}$ [cite: 28] |
The quarterly profitability metrics benefited from a \$17 million net income and \$20 million operating income benefit from one-time tariff refunds, which added approximately \$0.06 to diluted earnings per share and $110\text{ basis points}$ to the operating margin [cite: 28]. Excluding this effect, the normalized core operating margin was $27.2\%$, showing flat sequential performance compared with the fourth quarter of fiscal 2025 [cite: 18, 33].
Segment Contribution to Net Revenue (Q3 FY26)
LDG (Life Sciences & Diagnostics) [==================] $746M (39.7%)
ACG (Agilent CrossLab Group) [====================] $786M (41.9%)
AMG (Applied Markets Group) [=======] $346M (18.4%)
Segment results for the third quarter of fiscal 2026 were as follows:
* Life Sciences and Diagnostics Markets Group: Net revenue reached \$746 million, up $11\%$ reported (10% core), with an operating margin of $23.5\%$, supported by strong biopharma demand and the integration of Biocare Medical [cite: 12, 28, 31].
* Agilent CrossLab Group: Net revenue reached \$786 million, representing growth of $6\%$ reported (5% core), with a high operating margin of $34.3\%$, driven by steady consumables demand and service execution [cite: 28, 31].
* Applied Markets Group: Net revenue reached \$346 million, up $7\%$ reported (7% core), with an operating margin of $24.9\%$, driven by steady demand from environmental testing laboratories [cite: 28, 31, 33].
Following these results, management raised its full-year fiscal 2026 outlook [cite: 28, 31]. Revenues are now expected to range between \$7.49 billion and \$7.51 billion, representing core growth of $5.8\%$ to $6.0\%$ and reported growth of $7.8\%$ to $8.1\%$, representing an increase of $65\text{ basis points}$ at the midpoint of prior expectations [cite: 27, 28, 31].
Full-year non-GAAP diluted earnings per share guidance was adjusted upward to a range of \$6.18 to \$6.21, a \$0.15 increase at the midpoint from the prior range of \$6.00 to \$6.10, inclusive of the \$0.06 tariff-refund benefit [cite: 28, 31, 34].
For the fourth quarter of fiscal 2026, the company expects revenues between \$1.98 billion and \$2.0 billion (growth of $5.2\%$ to $6.2\%$ core), and non-GAAP earnings per share in the range of \$1.71 to \$1.74 [cite: 27, 31].
| Guidance Metric | Prior Full Year FY2026 Projections | Updated Full Year FY2026 Projections | Change at Midpoint |
|---|---|---|---|
| Consolidated Revenue | \$7.39 Billion – \$7.49 Billion [cite: 34, 35] | \$7.49 Billion – \$7.51 Billion [cite: 28, 31] | $+\$60\text{ Million}$ [cite: 28, 31] |
| Core Revenue Growth % | $+4.5\%$ – $+6.0\%$ [cite: 34, 35] | $+5.8\%$ – $+6.0\%$ [cite: 28, 31] | $+65\text{ bps}$ [cite: 28, 31] |
| Non-GAAP Diluted EPS | \$6.00 – \$6.10 [cite: 34, 35] | \$6.18 – \$6.21 [cite: 28, 31] | $+\$0.15$ per share [cite: 28, 31] |
| Non-GAAP Op. Margin Expansion | $+85\text{ bps}$ Sequential [cite: 34] | Over $+130\text{ bps}$ YoY [cite: 28, 31] | $+45\text{ bps}$ [cite: 28, 31] |
During the earnings call, CEO Padraig McDonnell highlighted that improving end-market conditions, strong customer demand in key regions, and positive momentum from the Ignite operating system supported the company's confidence in its raised outlook [cite: 31].
The corporate leadership team has undergone significant changes over the past year, with Adam Elinoff appointed as CFO in late 2025 (joining from Amgen) [cite: 36, 37], Tim Downs appointed as Vice President and Chief Accounting Officer in May 2026 [cite: 38], and Michael Buckner named Chief Legal Officer [cite: 36, 39].
The earnings announcement had a positive impact on market sentiment [cite: 14]. The stock rose $3.82\%$ in the regular trading session following the release to close at \$155.16 [cite: 14, 40], before climbing an additional $4.48\%$ to reach \$162.02 in after-hours trading [cite: 41]. Analyst target prices have shifted upward, establishing a median target price of \$159.32 with a consensus rating of "Moderate Buy" [cite: 42, 43].
To connect valuation to the core business model, the enterprise currently has an enterprise value of approximately \$43.52 billion, representing an enterprise-value-to-EBITDA multiple of $23.45\times$ and a forward P/E ratio of $23.10\times$ based on the midpoint of the revised fiscal year 2026 projections [cite: 43].
The company's historical five-year compound annual growth rate for revenue has been approximately $5.4\%$ [cite: 44]. This growth rate, combined with strong free cash flow conversion driven by recurring ACG sales, helps justify the company's valuation premium [cite: 10, 44].
| Key Valuation Multiple | Consolidated Multiples (Aug 2026) | Historical 5-Year Average Range |
|---|---|---|
| Trailing P/E Ratio (LTM) | $29.29\times$ – $31.93\times$ [cite: 43, 45] | $24.0\times$ – $28.0\times$ [cite: 46] |
| Forward P/E Ratio | $23.10\times$ [cite: 43] | $21.0\times$ – $24.0\times$ [cite: 46] |
| Enterprise Value to EBITDA | $23.45\times$ [cite: 43] | $18.0\times$ – $22.0\times$ [cite: 46] |
| Price to Free Cash Flow | $37.93\times$ [cite: 43] | $30.0\times$ – $35.0\times$ [cite: 46] |
The company's performance is closely tied to the integration of major acquisitions, specifically the \$925 million acquisition of BIOVECTRA in late 2024 and the \$950 million cash acquisition of Biocare Medical in mid-2026 [cite: 2, 7]. Successful execution requires integrating Biocare’s low-throughput automated immunohistochemistry systems and proprietary oncology antibody menu with the company's existing high-throughput pathology distribution network [cite: 12, 22]. Failure to achieve these commercial synergies could lead to goodwill impairment charges and delay projected earnings growth [cite: 2, 22].
The competitive landscape is subject to significant changes, such as the \$17.5 billion merger of Waters Corporation and BD Biosciences in 2026 [cite: 21]. This transaction creates a pro forma competitor with substantial diagnostic scale, putting competitive pressure on Agilent's clinical diagnostic validation programs [cite: 21]. Increased pricing competition from consolidated peers could lead to gross margin contraction in key product categories [cite: 10].
The company has significant exposure to the pharmaceutical and biotechnology sectors, which represent approximately $36\%$ of total revenues [cite: 10]. While the company's direct exposure to National Institutes of Health funding is minimal (representing approximately $1\%$ of sales), tightening credit conditions and budget constraints within the broader biopharma space could lead customers to defer laboratory equipment replacement cycles, impacting top-line growth [cite: 10].
The diagnostics and clinical pathology segments are subject to strict regulatory oversight from global health authorities, including the FDA and European regulatory bodies [cite: 2, 3]. Delays in companion diagnostic approvals or regulatory compliance issues at major manufacturing facilities could halt product shipments and impact the company's brand equity [cite: 2, 22].
The company's active M&A strategy has led to an increase in total debt, which reached \$3.949 billion as of July 31, 2026, compared to \$3.354 billion at the end of fiscal 2025 [cite: 27, 43]. While the current net leverage ratio of $1.7\times$ EBITDA remains conservative, a severe operational downturn could reduce capital allocation flexibility, potentially restricting future share repurchases or strategic R&D spending [cite: 10, 44].
With significant international operations, the company is sensitive to currency fluctuations, wage inflation, and trade policies [cite: 4, 31]. The introduction of import tariffs remains a key sensitivity; for example, tariff costs contributed to a $190\text{ basis point}$ decline in gross margin in fiscal year 2025 [cite: 17, 47]. The business is actively implementing supply chain adjustments to mitigate these tariff impacts and bring manufacturing closer to major customer hubs [cite: 17].
A global macroeconomic recession, accompanied by a sharp contraction in venture capital funding for early-stage biotechnology firms, could lead to a halt in major laboratory equipment capital expenditures [cite: 10, 17]. This would restrict the company's growth options and likely offset the positive impacts of the aging instrument replacement cycle [cite: 17, 33].
Key indicators of potential operational stress include:
* A sequential deceleration in Agilent CrossLab Group core revenue growth below $3\%$ [cite: 28, 31].
* An unexpected accumulation of raw material and finished goods inventories relative to sales growth, signaling potential oversupply [cite: 27, 48].
* A sequential contraction in core operating margins, excluding the impact of one-time tariff refunds [cite: 33].
The long-term thesis would be compromised if Waters Corporation's BD diagnostics integration results in a structural loss of market share for Agilent's high-performance liquid chromatography and diagnostics business [cite: 6, 21]. Additionally, structural margin degradation below the $21\%$ operating margin target would indicate a failure of the Ignite operating system to offset rising tariff costs and operational complexity [cite: 15, 47].
The 5-year scenario analysis projects key financial metrics to fiscal year 2031 (Year 5), utilizing the revised fiscal year 2026 expectations as Year 0 (Revenue $\$7.50$ billion, Non-GAAP EPS $\$6.20$, and outstanding shares of $282.4$ million) [cite: 46]. Returns are calculated based on the current share price of $\$155.16$ [cite: 40], assuming a cumulative dividend contribution of $\$5.50$ per share over the 5-year period [cite: 46].
The Base Case assumes a stable economic recovery, consistent execution under the Ignite operating system, and mid-single-digit core revenue growth [cite: 10, 33].
The High Case assumes an accelerated instrument replacement cycle, significant market share gains following the Waters-BD merger integration, and strong tailwinds from the reshoring of biopharma capacity [cite: 2, 17, 21].
The Low Case assumes persistent geopolitical trade tensions, slower biotech funding, and margin compression from rising import tariffs [cite: 17, 31].
Projected Share Price (USD)
$300 | --- High Case: $267.46
$250 |
$200 | --- Base Case: $192.84
$150 | --- Current: $155.16
$100 | --- Low Case: $116.96
|_________________________________________________
Year 0 Year 5
The probability-weighted share price target is calculated as:
$\text{Probability-Weighted Price Target} = (0.60 \times 192.84) + (0.20 \times 267.46) + (0.20 \times 116.96) = \$192.58\text{ USD}$
This probability-weighted target price implies a potential capital appreciation of $24.12\%$ over the current share price of $\$155.16$ [cite: 40].
| Scenario | Revenue in Year 5 | Margin / earnings assumption | Valuation multiple assumption | Current share price | Implied future share price | 5-year total return | Annualized return | Probability |
|---|---|---|---|---|---|---|---|---|
| Base Case [cite: 46] | $\$10.037\text{ B}$ | $21.5\%$ Net Margin / $\$8.04\text{ EPS}$ | $24.0\times\text{ P/E}$ | $\$155.16$ | $\$192.84$ | $27.83\%$ | $5.03\%$ | $60\%$ |
| High Case [cite: 46] | $\$11.277\text{ B}$ | $23.0\%$ Net Margin / $\$9.91\text{ EPS}$ | $27.0\times\text{ P/E}$ | $\$155.16$ | $\$267.46$ | $75.92\%$ | $11.96\%$ | $20\%$ |
| Low Case [cite: 46] | $\$8.695\text{ B}$ | $19.5\%$ Net Margin / $\$6.16\text{ EPS}$ | $19.0\times\text{ P/E}$ | $\$155.16$ | $\$116.96$ | $-21.07\%$ | $-4.62\%$ | $20\%$ |
| Weighted Target | — | — | — | $\$155.16$ | $\$192.58$ | $24.12\%$ | $4.42\%$ | $100\%$ |
CONSTRUCTIVE INVESTMENT HORIZON
Rating scores evaluate the long-term qualitative positioning, financial health, and governance structure of the enterprise [cite: 10, 44, 49].
CEO Padraig McDonnell has a 2.25-year tenure following his appointment in May 2024 [cite: 49]. His annual compensation of $\$12.83\text{ million}$ is heavily weighted toward stock and option awards ($91.1\%$), linking his financial incentives with shareholder returns [cite: 49]. McDonnell directly owns 0.023% of outstanding shares, valued at approximately $\$10.47\text{ million}$ [cite: 49]. While executive compensation is tied to key performance indicators like organic revenue growth, operating margin, and relative Total Shareholder Return, insider selling activity over the past year suggests a slightly more conservative alignment score [cite: 49, 50].
The revenue stream is of high quality, supported by a significant proportion of recurring consumables and service contracts, which represent approximately $65\%$ of consolidated revenues [cite: 10]. This recurring revenue stream, managed through the Agilent CrossLab Group, provides substantial top-line visibility and cash flow resilience through economic cycles [cite: 5, 10]. It is well-diversified across geographic regions and customer industries [cite: 10].
The company holds leading positions across its core markets, commanding approximately $20\%$ of the consolidated analytical laboratory supply industry [cite: 11]. However, Waters Corporation's recent acquisition of the BD Biosciences division for $\$17.5\text{ billion}$ has altered the competitive balance, creating a larger competitor in key biological workflows [cite: 21]. While the acquisition of Biocare Medical strengthens the organization's position in clinical pathology, competitive pressures in the high-performance liquid chromatography space remain elevated [cite: 2, 6, 24].
The secular growth outlook is supported by a large addressable market, an aging instrument replacement cycle, and nearshoring trends in domestic manufacturing [cite: 10, 17]. These drivers are supplemented by strategic, high-growth acquisitions like BIOVECTRA and Biocare Medical [cite: 2, 7]. However, broader macroeconomic sensitivities, potential tariff fluctuations, and slower Chinese market demand could act as near-term headwinds [cite: 9, 31].
The financial position of the enterprise remains sound, with a cash balance of $\$1.758\text{ billion}$ as of July 31, 2026, offsetting a total debt load of $\$3.949\text{ billion}$ [cite: 27]. The balance sheet supports strong liquidity, with a current ratio of $2.10\times$ and a net leverage ratio of $1.7\times$ EBITDA, which is well below the conservative rating agency threshold of $2.5\times$ [cite: 10, 43].
The business demonstrates long-term viability, protected by high customer switching costs and a highly regulated customer environment [cite: 11]. The proprietary software and hardware ecosystems of the company are deeply integrated into the daily workflows of global laboratories [cite: 5]. This regulatory and operational integration creates a highly durable business model with limited disruption risk from new entrants [cite: 11].
Management employs a balanced capital allocation strategy, prioritizing high-yield R&D investments (~8% of sales) and strategic M&A (Biocare Medical, BIOVECTRA) [cite: 2, 7, 11]. Surplus cash flow is consistently returned to shareholders through steady dividend growth and opportunistic share buybacks under a $\$2.0\text{ billion}$ authorized program [cite: 4, 10].
Sell-side sentiment is positive, with 15 analysts holding a "Buy/Strong Buy" rating out of a 21-analyst coverage group [cite: 42, 43]. Revisions have turned positive following the strong third-quarter print, leading to an upward revision in the consensus price target to approximately $\$159.32$ [cite: 29, 43].
The enterprise has compiled a solid track record of value creation, demonstrating consistent margin expansion through the execution of the Ignite Operating System [cite: 10, 33]. Operating cash flow remains strong relative to net income, reflecting efficient working capital management and strong cash conversion characteristics [cite: 44, 47].
$\text{Blended Score} = \frac{8+9+8+7+8+9+8+8+8}{9} = 8.11 / 10.0$
The qualitative score highlights the company's solid operational foundation, driven by its high recurring revenue quality and deep integration with global clinical and pharmaceutical laboratories [cite: 10, 11]. These strengths help balance the competitive risks associated with ongoing sector consolidation [cite: 10, 21].
DEFENSIVE MARKET LEADER
The company's long-term operational framework remains supported by its strong positioning in regulated laboratory environments, where high customer switching costs help secure recurring revenue [cite: 10, 11]. The integration of the Ignite operating system has improved pricing realization and operational margins, helping the business manage global trade and tariff pressures [cite: 15, 17].
Key growth catalysts include:
* Positive momentum from the core chromatography replacement cycle, which supports high-margin CrossLab sales [cite: 17].
* The reshoring of biopharma and semiconductor manufacturing capacity to the US, which management expects to expand the company's addressable market [cite: 17].
* The strategic integration of Biocare Medical, which strengthens the companion diagnostics and tissue-staining portfolio against clinical competitors [cite: 2, 12, 24].
These opportunities are balanced by key risks, such as competitive pressure following the Waters-BD Biosciences merger, rising total debt, and the execution requirements of recent acquisitions [cite: 10, 21, 27].
On balance, the company's high recurring revenue base and positive momentum under the Ignite framework support its constructive long-term outlook [cite: 10, 15].
STRONG SECULAR POSITIONING
The stock exhibits positive short-term momentum, trading at $\$155.16$ at the close on August 26, 2026, positioning it above its 50-day and 200-day simple moving averages of $\$138.55$ and $\$126.47$ [cite: 42]. This upward trend was supported by a strong third-quarter earnings report, which led to a $4.48\%$ increase in after-hours trading to $\$162.02$ [cite: 29, 41]. While short-term overbought signals suggest the potential for brief consolidation, upward revisions to full-year revenue and non-GAAP EPS guidance are expected to support price levels in the near term [cite: 28, 31, 51].
UPWARD BREAKOUT SUSTAINED
View Agilent Technologies, Inc. (A) stock page
Loading the interactive version of this report…